Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3

BACKGROUND: In phase III TIVO-3 trial, tivozanib improved progression-free survival (PFS) compared to sorafenib for patients with metastatic renal cell carcinoma (mRCC). However, the effectiveness of this drug after exposure to other selective VEGFR agents has not yet been defined. Herein, we charac...

Descripción completa

Detalles Bibliográficos
Autores principales: Meza, Luis, McDermott, David F, Escudier, Bernard, Hutson, Thomas E, Porta, Camillo, Verzoni, Elena, Atkins, Michael B, Kasturi, Vijay, Pal, Sumanta K, Rini, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020797/
https://www.ncbi.nlm.nih.gov/pubmed/36576430
http://dx.doi.org/10.1093/oncolo/oyac255

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020797/
https://www.ncbi.nlm.nih.gov/pubmed/36576430
http://dx.doi.org/10.1093/oncolo/oyac255

Ejemplares similares